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Abstract: The most common bone disorder found by implant dentists is osteoporosis, which is a systemic skeletal 
disorder associated with aging, which is characterized by loss of bone mass, making bones fragile and more 
susceptible to fractures. The World Health Organization has defined osteoporosis as a bone mineral density level 
greater than 2.5 standard deviations below the mean of young normal women. After 60 years of age, a third of the 
population have this disorder, it occurs twice as often in women than in men. It is estimated that 1.3 million 
fractures and 133,000 all hip fractures occur every year as a result of osteoporosis. The aim of this study was to 
discuss aspects of the pharmacological action of Bisphosphonates (BP) and their influence on the bone tissue when 
associated with treatment with dental implants. There are several types of treatments which prevent or prevent 
the progression of osteoporosis. So, BP, such as alendronate, are inhibitors of bone resorption. Act as controlling 
the development of osteoporosis by increasing the process of bone density and decrease its reabsorption, often 
acting as supporting the process of osseointegration of dental implants. 
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1. Introduction 
 The aim of Modern Dentistry is to restore 
normal comfort, function, aesthetics, phonation, and 
health to the patient. What makes Implantology 
unique is the ability to achieve this goal, however, the 
more teeth a patient loses the more challenging the 
task becomes [1-3]. It is estimated that the number of 
dental implants used in the United States increased by 
more than 10 times from 1983 to 2002 and another 
five times from 2000 to 2005 [5]. More than one 
million dental implants are performed each year [6]. 
The high need and use of treatments related to 
implants result from the combined effect of several 
factors and the most important are: (1) aging 
population with longer life expectancy, and (2) age-
related dental floss [6]. 
       In this sense, one of the major causes of 
osteopenia in women over 60 years of age is estrogen 
deficiency. This deficiency associated with aging 
causes an osteoporotic picture. A hormone 
replacement is necessary for an adequate treatment of 
the symptoms of menopause and to prevent possible 
osteoporosis [5, 6]. There are some drugs that help in 
the treatment of postmenopausal osteoporosis, they 
are calcitonin, bisphosphonates (BP) and the selective 
modulators of estrogen receptors [6]. Thus, BP has 
been the best drug associated with significant 
improvement in the quality of life of patients with bone 
diseases such as Paget's disease, bone metastases, 
osteogenesis imperfecta, hypercalcemia and even 
severe osteoporosis [6]. 
These drugs are used worldwide in cancer 
patients and are given intravenously as zoledronic acid 
(Zometa®). They canalso be administered orally, such 
as alendronate (Fosamax®) and risedronate 
(Actonel®) for the treatment of postmenopausal 
osteoporosis Duarte, Nociti, (2004). In 2003, a side 
effect associated with the use of BP with oral 
manifestation called Osteonecrosis Associated with BP 
was described for the first time [7]. 
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In this context, osteoporosis is a prevalent 
global bone disease in human aging. BPs are 
commonly used as therapy because they influence 
calcium metabolism of hard and soft tissues. 
Mucosal and dermal ulceration with exposure 
of the underlying bone results from incomplete 
epithelial recovery due to reduced desmosome 
formation due to lack of available calcium. However, 
pathological situations, such as BP-related jaw 
osteonecrosis, have been described. This hypothesis 
states other situations that require intact functional 
desmosomes such as skin healing over chronic 
pressure points leading to pressure ulcers and 
hemidesmosomes such as epithelial seals in contact 
with titanium surfaces will have a higher prevalence of 
collapse among patients treated with BP. This can be 
proven by the decreased modulation of calcium ions 
due to BP and its effect on intercellular communicating 
junction formation [4]. 
As yet another example of literary support, 
one paper reported a type of localized osteonecrosis 
that can occur in patients who had successfully Osseo 
integrated implants for many years and then started 
anti-resorptive therapy. Eleven female patients who 
successfully implanted but were placed on anti-
resorptive therapy (BPs or denosumab) several years 
later and developed osteonecrosis around the implants 
were identified. In each case, osteonecrosis occurred 
only around the implants and not around the patient's 
remaining teeth. Implants from eight patients were 
removed with bone sequestration firmly attached to 
the implant. This is different from the normal pattern 
of implant failure. Implant failure can occur when 
patients with successfully integrated implants are 
subsequently placed on anti-resorption therapy, and 
osteonecrosis takes on a particular form where a 
sequestration forms that remain adherent to the 
implant. Why the remaining adjacent teeth are not 
affected is unclear [5]. 
Therefore, the present study reviewed the 
literature analyzing the use of BP associated with 
dental implants, because it is a possible alternative for 
the reduction of loss and increase in bone density, as 
well as for the possibility of osteonecrosis, which 
requires therapeutic and preventive measures in the 




Experimental and clinical studies were included 
(case reports, retrospective, prospective and 
randomized trials) with qualitative and quantitative 
analysis. Initially, the key words were determined by 
searching the DeCS tool (Descriptors in Health 
Sciences, BIREME base) and later verified and 
validated by MeSh system (Medical Subject Headings, 
the US National Library of Medicine) in order to 
achieve consistent search. 
 
2.1. Mesh Terms 
The descriptors included were Osteoporosis. 
Osteonecrosis. bone resorption. Osseointegration. 
Dental implant. Complications. The literature search 
was conducted through online databases: PubMed, 
Scopus, Web of Science e Embase, Cochrane, Ovid, 
Periodicos.com, Harvard Library and Google Scholar. 
The risk of BIAS in the present study was not 
analyzed. 
 
2.2. Series of Articles and Eligibility 
A total of 79 articles were found involving the 
MeSH Terms. Initially, it was held the exclusion 
existing title and duplications in accordance with the 
interest described this work. After this process, the 
summaries were evaluated and a new exclusion was 
held. A total of 46 articles were evaluated in full, and 
29 were included and discussed in this study. 
 
3. Development and Literature Review 
3.1. Osteoporosis, Osseointegration and 
Dental Implants - Concept and 
Epidemiology 
Osteoporosis is defined as a systemic skeletal 
disorder, associated with aging, characterized by loss 
of bone mass, which makes the bone more fragile and 
more prone to fractures [13]. The World Health 
Organization defined osteoporosis as a level of bone 
mineral density greater than 2.5 standard deviations 
below the average of normal young women [17-20]. 
After 60 years of age, a third of the population has this 
disorder, it occurs twice more in women than in men 
and its diagnosis is made with greater prevalence from 
the third decade of life. 
Among the systemic alterations, osteoporosis 
is one of the dysfunctions commonly found by implant 
dentists [17]. Osteoporosis acts by modifying the 
metabolism of the bone tissues, disorganizing the 
trabecular architecture of the cortical and alveolar 
bone, which are responsible for the tooth support. It is 
estimated that 1.3 million of all fractures and 133,000 
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of hip fractures occur each year as a result of 
osteoporosis [20]. 
Osteoporosis can be classified as type I and 
type II. Type I (postmenopausal) occurs when there is 
loss of trabecular bone mass, resulting in fractures of 
the vertebrae and wrists, which may be more evident 
in the mandible and in the alveolar bone, is associated 
with the aging and plasma decrease of estrogen in the 
menopause, affecting mainly women; And Type II 
(senile), occurs when there is loss of trabecular bone 
mass that can affect both cortical and spongy bone, 
resulting in hip fractures, which can affect both sexes 
and in ages over 70 years [12-17]. 
There is a higher prevalence of the 
development of osteoporosis in women, and there are 
some risk factors that may explain this difference, such 
as early menopause, artificial menopause, nulliparous 
and estrogen replacement [21-24]. For men, reduced 
testicular function (male hypogonadism) can be cited 
as a risk factor. There are several other risk factors 
that may predispose to both sexes: heredity, tobacco, 
alcohol, caffeine, obesity, absence of physical activity, 
ethnicity, changes in calcium levels, malnutrition, 
decreased levels of vitamin D, elevated Levels of 
parathyroid hormone and other hormones, all these 
factors may manifest in both men and women with 
osteoporosis [13,17]. 
The recommended intake of calcium is 800 mg 
day-1, in women who have already gone through 
menopause, 1.5 g may be required to maintain a 
positive calcium balance [25,26]. For patients with 
established osteoporosis, there are drugs that, in 
general, act directly in the process of bone remodeling, 
seeking to reduce bone resorption, among them, BP, 
which are drugs of proven efficacy that act in the 
prevention and treatment of several Bone diseases 
[26]. 
In this sense, dental implants are defined as 
supports or structures of titanium metal, which 
through surgeries are fixed in the maxillary bone 
replacing the dental roots, thus allowing the artificial 
teeth to fit the metal. Dentistry uses several 
rehabilitation techniques for masticatory functions, and 
Osseo integrated implants are considered safe, 
provided they are implanted in areas of good quantity 
and bone quality [12]. However, some systemic 
conditions may interfere with implant stability, such as 
osteoporosis. Implantology has shown increasing 
success rates when it presents a harmonious bone / 
implant relationship (osseointegration) [12]. 
The discovery of osseointegration occurred 
through studies of microcirculation in the bone marrow 
performed on the rabbit fibula, developed by Per-
Ingvar Branemark. He verified in Branemark's studies 
that a titanium implant when inserted into the 
medullary space, under certain conditions, and 
remained immobile without mechanical trauma during 
the period of bone repair, ends up full of compact 
bone without the interference of other tissues [13-15]. 
In this context, osteoporosis is a factor that 
retards the regeneration of maxillary bone in patients 
who have undergone implant surgery, prolonging the 
normal recovery time of maxillary bone that can vary 
from three to six months [25]. Therefore, it is 
necessary that people affected by this disease and who 
will receive dental implants need a longer time for 
bone repair [25]. Due to the increase in life 
expectancy, rehabilitation with implants in people over 
60 years old is the most common age group in which 
there is a higher probability of metabolic pathologies 
[26]. 
In order to obtain osseointegration of the 
implant, which is the direct and structural union of the 
bone tissue to the titanium and function, it is 
necessary to respect several principles, among them, 
those related to the surgical technique, respecting 
tissue physiology [24]. Thus, it is necessary to control 
the tremorgenic factors during surgery such as 
intensity, frequency and duration of the milling 
(osteotomies), which can generate excessive trauma to 
the bone tissue, impairing the bone repair potential of 
the injured area. Facing situations where the traumatic 
stimulus exceeds its physiological limit, the implant 
may be involved by fibrous connective tissues, leading 
to the formation of a bone or fibrous perimplant 
interface, without osseointegration [24]. 
For the success of osseointegratable implants 
other factors must also be considered, not only related 
to the professional (surgical technique), but also the 
industry and the patient himself. In addition to 
performing the appropriate surgical technique, it is up 
to the professional to select the patient, evaluating it 
as a whole, from his complaint, including his 
expectation regarding the treatment, mainly 
comprising his pre-operative systemic and local 
conditions [25,26]. At the moment of preparation of 
the receptor bone bed for the subsequent installation 
of the Osseo integrated implant, bone necrosis occurs, 
which will be replaced by new bone tissue. When there 
is osteoporosis, the process of bone remodeling can be 
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compromised, preventing or delaying osseointegration 
[26]. 
Several authors Ourique et al. [17] have 
already reported on the importance of knowledge of 
systemic alterations, so that necessary measures are 
taken to minimize or prevent eventual damages 
caused by osteoporosis in the anatomical, physiological 
and functional integrity of the alveolar bone. All care is 
necessary for the success of this process, since the 
immediate benefit of the rehabilitative treatment with 
implants is observed in the improvement of the 
capacity to crush the food, in the physical and 
psychological well-being of the patient. 
Ishii et al. [12] states that although 
osteoporosis is a significant factor that can interfere 
with bone volume and density, it cannot be considered 
as an absolute contraindication for implant installation. 
It is essential that during the anamnesis, all patients 
are questioned about their state of health, reporting 
the use of medications and the type of medical 
treatment they are undertaking, so that a safe and 
effective treatment plan is drawn up for each individual 
case. 
 
3.2. Bisphosphonate - Major Considerations 
BP are a widely used drug group for various 
bone disorders and have been approved by the U.S. 
Food and Drug Administration for the treatment of 
osteoporosis, metastatic bone cancer and Paget's 
disease [24]. They were first used for industrial 
purposes in the 19th century to prevent corrosion in 
the textile, fertilizer and oil industries. In 1968, the 
first paper describing the use of BP in medicine was 
published, however in 2002 serious side effects of 
these medications were reported following dental 
surgery procedures. This includes osteonecrosis, 
avascular necrosis, osteomyelitis, osteochimionecrosis, 
and maxillary Biss-Phossy [24]. 
At the moment there are two main types of 
BP: those containing nitrogen (oral: alendronate and 
risedronate, intravenous: pamidronate and 
zoledronate) and those that do not contain (etidronate, 
clodronate and tiludronate). BP act by suppressing and 
reducing bone resorption by osteoclasts, directly 
preventing the recruitment and function of osteoclasts, 
and indirectly stimulate osteoblasts to produce 
inhibitors of osteoclast formation [25]. 
BP are drugs derived from inorganic 
pyrophosphate, which are present in the body and 
physiologically regulate calcification and bone 
resorption. Pyrophosphate also provides greater 
resistance to chemical and enzymatic hydrolysis [15]. 
Camargo, Minosso, Lopes, (2007) [6] report that 
therapeutic treatment should always combine an anti-
resorptive agent with a non-pharmacological measure 
such as physical exercise and consumption of calcium 
and vitamin D by diet. Ant reabsorption agents are 
described by Ishii (2009) [12] as estrogen replacement 
therapy, selective estrogen receptor modulators, BP 
and calcitonin and also describes bone formation 
stimulating agents such as parathyroid hormone. 
Ourique et al. [17] have shown in their studies 
that calcium intake is associated with hormone 
replacement (estrogen), which leads to an increase in 
trabecular bone mass. Calcium when ingested alone is 
not able to definitively prevent the onset of 
osteoporosis. The authors also report that in addition 
to osteoporosis, age, sex, races, hormonal pattern, 
decreased vitamin D synthesis, inhibition of calcium 
absorption, parathormone increase, nicotine, fragile 
physical structure, renal deficiency, menopause, 
alcohol and low Consumption of calcium may 
jeopardize the success of an implant. 
BP, according to Ishii et al. [12] Are anti-
resorptive agents derived from pyrophosphoric acid 
that invalidate bone resorption. Ferreira Junior et al. 
[10] stated that BP can contain bone loss, increase 
bone density, and reduce the risk of fractures resulting 
from progressive loss of bone mass. In the BP group, 
alendronate is the most potent because it has an 
affinity for bone tissue. Another indication to prevent 
osteoporosis is calcitonin, which is a peptide derived 
from parafollicular thyroid cells, aiding bone resistance. 
Alendronate, for osteoporotic patients, can be 
administered orally at 10.0 mg / day or 70.0 mg / 
weekly, and cannot be exceeded because it causes 
gastrointestinal changes such as erosive esophagitis. It 
is necessary to use this medicine in fasting, for being 
little absorbed in the intestine, and to wait of 40 to 60 
minutes to feed. It is a drug that deposits about 40-
60% rapidly into the bone and the rest is released 
through the urine. The plasma half-life of BP is very 
short, ranging from thirty minutes to two hours, so 
after these medications are absorbed by the bone 
tissue, they may persist for more than 10 years in 
skeletal tissues [17]. 
A review study with Meta-Analysis included 
clinical human studies, randomized or not. A total of 
18 publications were included in the review. Regarding 
implant failure, the meta-analysis found a risk ratio of 
1.73 (95% confidence interval [CI] 1.21-2.48, p = 
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0.003) for BP patients when compared to patients who 
did not take the medicine. The probability of an 
implant failure in patients receiving BP was estimated 
at 1.5% (0.015, 95% CI 0.006-0.023, standard error 
[SE] 0.004, p<0.001). BP cannot be suggested to 
affect marginal bone loss from dental implants due to 
a limited number of studies reporting this result. Due 
to lack of sufficient information, the meta-analysis for 
the outcome "postoperative infection" was not 
performed. The results of the present study cannot 
suggest that dental implant insertion in patients taking 
BP affects implant failure rates due to a limited 
number of published studies, all characterized by a low 
level of specificity, and most of them dealing with a 
limited number of cases without an adequate control 
group. Therefore, the real effect of BP on 
osseointegration and survival of dental implants is not 
yet well established [3]. 
 
3.3. Bisphosphonates – Major 
Complications 
Ishii et al. [12] states that patients who use BP 
may have an impaired healing of the damaged dental 
implant as it impedes bone remodeling and may lead 
to a condition called osteonecrosis, which is considered 
a side effect of this drug. Although there are many 
data on the beneficial effects of BP in the treatment of 
advanced osseous diseases, numerous reports have 
documented the ability of these medications to cause 
local lesions of bone osteonecrosis mainly in the jaw 
[25].  
Osteonecrosis may remain asymptomatic for 
weeks and possibly months, and lesions usually 
develop around tapered areas and prior surgical sites, 
including extractions, retrograde apical tetanus, 
periodontal surgery, and dental implant surgery. 
Symptoms include pain, soft tissue edema, infection, 
tooth loss, and drainage. Radiographically, osteolytic 
changes are observed and tissue biopsy shows the 
presence of actinomyces [26].  
In the dental office, the most common BP that 
the implant is exposed are the oral ones that contain 
nitrogen, such as risedronate, ibandronate and 
alendronate. Comprehensive anamnesis is essential 
prior to the initiation of any elective treatment, the risk 
versus benefits of dental treatment should be 
discussed in detail with the patient [24]. 
In this context, another study using the BP 
analyzed the factors related to obtaining effective 
mechanical and immunological adhesion, viability, 
epidermal collagen growth factor, and immunoglobulin 
synthesis were evaluated. The presence of BP 
culminated in lower cell adhesion to titanium discs, 
particularly for sodium alendronate (SA) at 5 μM 
(40%) and zoledronic acid (ZA) at all concentrations 
(30 to 50% according to increased concentrations). 
Reduced cell viability occurred after an exposure of 
these cells to ZA (40%); however, only 5 μM of SA 
treated cells had decreased viability (30%). Reduced 
synthesis of growth factors and collagen was observed 
when cells were treated with ZA (20 and 40%, 
respectively), while about 70% of IgG synthesis was 
increased. BPs negatively affected adhesion and 
metabolism of oral mucosal cells, and this effect was 
related to BP type as well as concentration and 
treatment period. The negative effects of BPs on oral 
mucosa cells may hinder the formation of an effective 
biological seal in Osseo integrated implants [4]. 
Also, a review study aimed to study the 
purpose of dental implant placement in patients who 
have been treated or are undergoing treatment with 
BP medication. Outcome measures included implant 
failure or implant-related jaw osteonecrosis. In total, 
32 literature sources were reviewed, and 9 of the most 
relevant articles that fit the criteria were selected. 
Heterogeneity between studies was found and no 
meta-analysis could be performed. Five studies looked 
at intra-oral BP medication for implant placement, 
three studies looked at intravenous BP medication for 
implant placement, and one study evaluated the two 
types of medication administered for implant 
placement. Patients with intraoral therapy appeared to 
have better implant survival (5 implants failed 423) 
rate of 98.8% versus intravenously treated patients (6 
implants failed 68) by 91%; The control group 
compared with the intraoral BP group appeared with 
97% success in implant survival rate (27 implants 
failed in 842), showing no significant difference in 
implant placement success. Patients treated with 
intravenous BP appear to have a greater chance of 
developing implant-related jaw osteonecrosis. The 
intraorally treated group of patients appeared to have 
more successful results. Implant placement in 




In the present research, osteoporosis is a 
metabolic condition that affects alveolar bone density, 
but does not present problems for the installation of 
Osseo integrable implants, as long as there is sufficient 
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bone mass in the region where the tooth will be 
implanted. It suggests to the dental surgeons the 
knowledge of the diagnosis so that it makes a careful 
evaluation, directing the professional to observe the 
quality of the bone through routine image 
examinations. Further, alendronate sodium is used to 
decrease bone resorption, the drug should be 
considered as an adjunctive therapeutic agent for the 
treatment of osteoporosis. 
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